Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Left ventricular hypertrophy (LVH) is common in end-stage renal disease (ESRD) and has been advocated as a therapeutic target. We review the considerations for targeting LVH as a modifiable risk factor in ESRD.

Related collections

Author and article information

Journal

PubMed ID:: 25295959

PMC ID:: 4266593

DOI:: 10.1097/MNH.0000000000000067

Data availability:

Comments

Comment on this article

scite_

Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Read this article at

Alternative approaches to Alzheimer's Disease

Journal

Comment on this article